Log in

Iterum Therapeutics Stock Price, News & Analysis (NASDAQ:ITRM)

-0.06 (-1.64 %)
(As of 10/23/2019 09:13 AM ET)
Today's Range
Now: $3.60
50-Day Range
MA: $5.53
52-Week Range
Now: $3.60
Volume15,257 shs
Average Volume20,264 shs
Market Capitalization$50.26 million
P/E RatioN/A
Dividend YieldN/A
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of adults in uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:ITRM



Sales & Book Value

Annual Sales$870,000.00
Book Value$5.13 per share


Net Income$-77,060,000.00
Net Margins-11,956.64%


Market Cap$50.26 million
Next Earnings Date11/13/2019 (Estimated)
OptionableNot Optionable

Receive ITRM News and Ratings via Email

Sign-up to receive the latest news and ratings for ITRM and its competitors with MarketBeat's FREE daily newsletter.

Iterum Therapeutics (NASDAQ:ITRM) Frequently Asked Questions

What is Iterum Therapeutics' stock symbol?

Iterum Therapeutics trades on the NASDAQ under the ticker symbol "ITRM."

How were Iterum Therapeutics' earnings last quarter?

Iterum Therapeutics PLC (NASDAQ:ITRM) posted its quarterly earnings data on Wednesday, August, 14th. The company reported ($1.93) earnings per share for the quarter, missing the consensus estimate of ($1.50) by $0.43. Iterum Therapeutics had a negative return on equity of 136.21% and a negative net margin of 11,956.64%. View Iterum Therapeutics' Earnings History.

When is Iterum Therapeutics' next earnings date?

Iterum Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, November 13th 2019. View Earnings Estimates for Iterum Therapeutics.

What price target have analysts set for ITRM?

3 Wall Street analysts have issued 1-year target prices for Iterum Therapeutics' shares. Their predictions range from $17.00 to $20.00. On average, they anticipate Iterum Therapeutics' share price to reach $18.00 in the next twelve months. This suggests a possible upside of 400.0% from the stock's current price. View Analyst Price Targets for Iterum Therapeutics.

What is the consensus analysts' recommendation for Iterum Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iterum Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Iterum Therapeutics.

What are Wall Street analysts saying about Iterum Therapeutics stock?

Here are some recent quotes from research analysts about Iterum Therapeutics stock:
  • 1. According to Zacks Investment Research, "Iterum Therapeutics plc is a clinical-stage pharmaceutical company. It develops and markets therapies to address unmet medical needs, as well as provides anti-infectives to treat multi-drug resistant pathogens. The company's product pipeline consists of uncomplicated urinary tract infections, complicated urinary tract infections and complicated intra abdominal infections. Iterum Therapeutics plc is based in Dublin, Ireland. " (7/17/2019)
  • 2. HC Wainwright analysts commented, "Valuation We employ a rNPV model, shown below, to value ITRM at $17 per share. We estimate the current risk- adjusted per-share value of sulopenem across its three indications: (1) $6.44 for cUTI (68% POS; $244M peak revenues in 2035); (2) $5.31 for uUTI (65% POS; $179M peak sales in 2035); and (3) $5.46 for cIAI (68% POS; $153M peak sales in 2035)." (6/21/2019)
  • 3. Needham & Company LLC analysts commented, "Iterum reported 4Q18 financial results today. Mgmt reiterated guidance for top-line results from all three ongoing Phase 3 trials of sulopenem in 2H19 (complicated UTI, uncomplicated UTI, and complicated Intra- Abdominal Infections). We expect each trial to meet non-inferiority primary endpts, but acknowledge increased risk at reaching the secondary superiority endpt in the subset of patients w/ ciprofloxacin-resistant infections in the uUTI trial. Regardless, meeting primary non-inferiority endpts is sufficient for regulatory approval. The UTI market represents one of the most attractive opportunities in the antibiotic space due to absence of a sufficiently potent oral antibiotic coupled with a commercial opportunity that is large and primarily outside the hospital." (3/25/2019)

Has Iterum Therapeutics been receiving favorable news coverage?

Headlines about ITRM stock have been trending negative on Wednesday, InfoTrie Sentiment reports. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Iterum Therapeutics earned a news impact score of -2.5 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the near future. View News Stories for Iterum Therapeutics.

Are investors shorting Iterum Therapeutics?

Iterum Therapeutics saw a decrease in short interest in the month of September. As of September 15th, there was short interest totalling 81,200 shares, a decrease of 5.6% from the August 15th total of 86,000 shares. Based on an average daily trading volume, of 8,900 shares, the days-to-cover ratio is presently 9.1 days. Currently, 1.8% of the shares of the company are sold short. View Iterum Therapeutics' Current Options Chain.

Who are some of Iterum Therapeutics' key competitors?

What other stocks do shareholders of Iterum Therapeutics own?

Who are Iterum Therapeutics' key executives?

Iterum Therapeutics' management team includes the folowing people:
  • Mr. Corey N. Fishman, Pres, CEO & Director (Age 54)
  • Ms. Judith M. Matthews, Chief Financial Officer (Age 49)
  • Dr. Michael W. Dunne, Chief Scientific Officer (Age 59)
  • Mr. Benjamin M. Pe, VP of Operations

When did Iterum Therapeutics IPO?

(ITRM) raised $80 million in an IPO on Friday, May 25th 2018. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers.

How do I buy shares of Iterum Therapeutics?

Shares of ITRM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Iterum Therapeutics' stock price today?

One share of ITRM stock can currently be purchased for approximately $3.60.

How big of a company is Iterum Therapeutics?

Iterum Therapeutics has a market capitalization of $50.26 million and generates $870,000.00 in revenue each year. The company earns $-77,060,000.00 in net income (profit) each year or ($7.11) on an earnings per share basis. Iterum Therapeutics employs 48 workers across the globe.View Additional Information About Iterum Therapeutics.

What is Iterum Therapeutics' official website?

The official website for Iterum Therapeutics is http://www.iterumtx.com/.

How can I contact Iterum Therapeutics?

Iterum Therapeutics' mailing address is BLOCK 2 FLOOR 3 HARCOURT CENTRE HARCOURT STREET, DUBLIN L2, 2. The company can be reached via phone at 353-1903-8920 or via email at [email protected]

MarketBeat Community Rating for Iterum Therapeutics (NASDAQ ITRM)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  80 (Vote Outperform)
Underperform Votes:  87 (Vote Underperform)
Total Votes:  167
MarketBeat's community ratings are surveys of what our community members think about Iterum Therapeutics and other stocks. Vote "Outperform" if you believe ITRM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ITRM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/23/2019 by MarketBeat.com Staff

Featured Article: Lock-Up Period Expiration

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel